Stockscreener 앱 받기
5.07
7.82%
-0.43
시간 외 거래:
5.12
0.05
+0.99%
전일 마감가:
$5.50
열려 있는:
$5.61
하루 거래량:
161.62K
Relative Volume:
0.56
시가총액:
$30.22M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-7.99%
1개월 성능:
-36.94%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.01
$5.61
1주일 범위
$5.01
$6.4499
52주 변동 폭
$5.01
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
명칭
Vyome Holdings Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
HIND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
5.07 | 30.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vyome Holdings Inc 주식(HIND)의 최신 뉴스
Head-To-Head Comparison: Vyome (NASDAQ:HIND) vs. Bioventus (NASDAQ:BVS) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Maxim Group Reaffirms “Buy” Rating for Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Acquires AI Startup Oculo, Inc. - TipRanks
Vyome Holdings acquires Oculo Health - Medical Buyer
Vyome Holdings Acquires MIT Spinout Oculo Health, Launches AI Psychiatrist Business Unit - Sahyadri Startups
Vyome Holdings Acquires MIT AI Spinout Oculo Health - citybiz
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics By Investing.com - Investing.com South Africa
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics - Investing.com Nigeria
Vyome Holdings acquires MIT AI spinout Oculo Health - MarketScreener
Vyome shares surge after encouraging preclinical data for eye treatment - MSN
BC-Most Active Stocks - upstatetoday.com
Why Is BBAI Stock Falling Today? - Stocktwits
HIND Stock Rallies 70% Pre-Market Today Find Out Why - Menafn
HIND Stock: Growth or Bubble? - StocksToTrade
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Asianet Newsable
Vyome Holdings (HIND) Skyrockets Over 50% on Breakthrough Uveitis Treatment News - RagingBull
Vyome stock soars after positive preclinical results for eye drug - Investing.com India
Vyome stock soars after positive preclinical results for eye drug By Investing.com - Investing.com Nigeria
Morning Market Movers: SPRC, HIND, SQFT, FGNX See Big Swings - RTTNews
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity - Business Wire
Vertiv’s Stock Surge: Will it Last? - StocksToTrade
Vyome Holdings Appoints Dr. Richard Fahrner as CTO and Dr. Tamara Agajanov, MD, as SVP – Clinical Development - citybiz
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies - PharmiWeb.com
Vyome Holdings strengthens leadership team with industry veterans as it plans pivotal trial studies - MarketScreener
Vyome Holdings Completes Merger with Vyome Therapeutics - MSN
Vyome’s VT-1953 shows significant reduction in cancer wound odor By Investing.com - Investing.com Nigeria
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - biospace.com
Vyome’s VT-1953 shows significant reduction in cancer wound odor - Investing.com India
Vyome Holdings Inc positive interim data from Phase 2 Study of VT-1953 in malignant fungating wounds - MarketScreener
Vyome Holdings completes merger with Vyome Therapeutics and files financials By Investing.com - Investing.com Canada
Vyome Holdings completes merger with Vyome Therapeutics and files financials - Investing.com
Vyome Holdings, Embryyo Technologies Partner on AI Medtech - Medical Product Outsourcing
Vyome, Embryyo form partnership to pursue AI-enabled medical devices - Medical Economics
US-based Vyome signs MoU with India’s leading medical device innovation studio Embryyo - BioSpectrum India
Vyome And Embryyo Sign MoU To Develop AI-Enabled Medical Devices - Sahyadri Startups
Vyome Holdings, Inc. Signs MoU with Embryyo Technologies - MarketScreener
Vyome, India's Embryyo Sign MOU to Pursue AI Medical Device Market; Shares up Pre-Bell - MarketScreener
Vyome partners with Embryyo to enter AI-enabled medical device market - Investing.com
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio - FinancialContent
Vyome Holdings expands at-the-market offering and appoints new auditor - Investing.com India
Vyome Holdings expands at-the-market offering and appoints new auditor By Investing.com - Investing.com South Africa
Vyome Holdings Amends Equity Distribution Agreement - TipRanks
Vyome Amends Equity Distribution Agreement with ReShape Lifesciences Inc. - AInvest
Vyome Holdings Inc (HIND) 재무 분석
Vyome Holdings Inc (HIND)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):